About the REIMAGINE program REIMAGINE is a phase 3 clinical development program with once-weekly subcutaneous CagriSema in type 2 diabetes
Key Areas of Research: Structural: collagen, matrix, connective tissue Dermatological: wound healing, skin regeneration, hair growth Systemic: inflammation, repair, recovery Together, these findings suggest broad experimental potential for GHK-Cu across structural, dermatological, and systemic pathways
This allows the solution to disperse and prevents leakage
The combination of all four pathways should theoretically produce earlier onset of appetite suppression, more sustained fullness between meals, increased resting energy expenditure from the glucagon component, and a reduced tendency toward the metabolic adaptation that commonly causes weight loss plateaus on single-agent therapy